A short account of metastatic bone disease

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Feller, Liviu ^a   Kramer, Beverley ^b   Lemmer, Johan ^a  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bone metastasis; Jaw; PTHrP

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; PYRIDINOLINE; SIALOPROTEIN; SOMATOMEDIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; VITRONECTIN;

BONE ATROPHY; BONE DENSITY; BONE DESTRUCTION; BONE MASS; BONE MATRIX; BONE METASTASIS; BONE MINERALIZATION; BONE PAIN; BONE REMODELING; BONE TURNOVER; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; HUMAN; HYPERCALCEMIA; JAW CANCER; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIMARY TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD COMPRESSION; T LYMPHOCYTE; UPREGULATION;

EID: 79960690904     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-24     Document Type: Review

References (60)

1. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
2. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359:2814-2823. 10.1056/NEJMra0805239, 19109576.
3. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55. 539194, 15630443.
4. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003, 100:7737-7742. 10.1073/pnas.1331931100, 164657, 12808139.
5. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68. 10.1016/j.ccr.2007.12.003, 18167340.
6. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284. 10.1038/nrc2622, 19308067.
7. Feller L, Bouckaert M, Chikte UM, Wood NH, Khammissa RA, Meyerov R, Lemmer J. A short account of cancer--specifically in relation to squamous cell carcinoma. SADJ 2010, 65:322-324.
8. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5:21-28. 10.1038/nrc1528, 15630412.
9. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007, 8:341-352.
10. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005, 19:228-230.
11. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 2009, 9:272. 10.1186/1471-2407-9-272, 2739221, 19660124.
12. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67:61-73. 10.1002/pros.20500, 17034033.
13. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008, 22:559-574. 10.1101/gad.1636908, 2731657, 18316475.
14. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006, 25:573-587.
15. Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 2007, 117:2351-2361. 10.1172/JCI31791, 1952634, 17786228.
16. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006, 66:11089-11093. 10.1158/0008-5472.CAN-06-2407, 2952469, 17145848.
17. Pienta KJ, Loberg R. The "emigration, migration, and immigration"of prostate cancer. Clin Prostate Cancer 2005, 4:24-30.
18. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005, 20:318-329.
19. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005, 5:S46-S53. 10.3816/CBC.2005.s.004, 15807924.
20. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593. 10.1038/nrc867, 12154351.
21. Schwartz GG. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 2008, 17:478-483. 10.1158/1055-9965.EPI-07-2747, 18349265.
22. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847, 14695408.
23. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005, 65:8274-8285. 10.1158/0008-5472.CAN-05-1891, 16166304.
24. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 2008, 27:596-603. 10.1038/sj.onc.1210694, 17700537.
25. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001, 20:333-349. 10.1023/A:1015599831232, 12085970.
26. Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 2002, 4:24-29. 138712, 11879556.
27. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004, 11:207-224. 10.1677/erc.0.0110207, 15163299.
28. Bringhurst F, Demay M, Krane S, Kronenberg H. Bone and Mineral Metabolism in Health and Disease. Harrison's Principles of Internal Medicine 2008, 2365-2376. New York: McGraw-Hill, Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J, 17.
29. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261. 10.1002/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U, 10344214.
30. Bai YD, Yang FS, Xuan K, Bai YX, Wu BL. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Med Hypotheses 2008, 71:256-258. 10.1016/j.mehy.2008.03.021, 18445511.
31. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831, 15084698.
32. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764. 10.1016/j.devcel.2005.02.017, 15866165.
33. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J 2009, 39:110-116. 10.1111/j.1445-5994.2008.01732.x, 19356186.
34. Fenton R, Longo D. Cancer Cell Biology and Angiogenesis. Harrison's Principles of Internal Medicine 2008, 498-513. New York: McGraw-Hill, Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J, 17.
35. Biskobing DM, Fan X, Rubin J. Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res 1995, 10:1025-1032.
36. Yagiz K, Rittling SR. Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. Exp Cell Res 2009, 315:2442-2452. 10.1016/j.yexcr.2009.05.002, 2704245, 19427849.
37. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible forb osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s. 10.1158/1078-0432.CCR-06-1007, 17062703.
38. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88:2892-2898. 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y, 10898330.
39. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000, 5:75-81. 10.1007/s007760050012, 10664443.
40. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999, 17:163-170. 10.1023/A:1006689719505, 10411109.
41. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999, 59:4453-4457.
42. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R. Osteoclasts are active in bone forming metastases of prostate cancer patients. PloS one 2008, 3:e3627. 10.1371/journal.pone.0003627, 2574033, 18978943.
43. Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol 2008, 214:394-404.
44. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005, 173:10-20. 10.1097/01.ju.0000141582.15218.10, 15592017.
45. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005, 23:8232-8241. 10.1200/JCO.2005.03.0841, 16278478.
46. Feller L, Wood NH, Khammissa RA, Chikte UM, Bouckaert M, Lemmer J. Bisphosphonate-related osteonecrosis of the jaw. SADJ 2011, 66:30-32.
47. Barton MK. Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin 2011, 61:135-136. 10.3322/caac.20116, 21532096.
48. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008, 34:629-639. 10.1016/j.ctrv.2008.05.001, 3090688, 18579314.
49. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69. 10.1093/jnci/dji002, 15632381.
50. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005, 2:504-517.
51. Seibel MJ. The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clin Endocrinol 2008, 68:839-849.
52. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006, 66:2031-2058. 10.2165/00003495-200666160-00001, 17112299.
53. Huang Q, Ouyang X. Biochemical-markers for the diagnosis of bone metastasis: A review in clinical. Cancer Epidemiol 2011,
54. Hirshberg A, Leibovich P, Buchner A. Metastatic tumors to the jawbones: analysis of 390 cases. J Oral Pathol Med 1994, 23:337-341. 10.1111/j.1600-0714.1994.tb00072.x, 7815371.
55. D'Silva NJ, Summerlin DJ, Cordell KG, Abdelsayed RA, Tomich CE, Hanks CT, Fear D, Meyrowitz S. Metastatic tumors in the jaws: a retrospective study of 114 cases. J Am Dent Assoc 2006, 137:1667-1672.
56. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol 2008, 44:743-752. 10.1016/j.oraloncology.2007.09.012, 18061527.
57. Irani S. Metastasis to head and neck area: a 16-year retrospective study. Am J Otolaryngol 2011, 32:24-27. 10.1016/j.amjoto.2009.09.006, 20031269.
58. van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003, 41:3-6. 10.1016/S0266-4356(02)00301-7, 12576032.
59. Ertas U, Yalcin E, Erdogan F. Invasive ductal carcinoma with multiple metastases to facial and cranial bones: a case report. Eur J Dent 2010, 4:334-337. 2897869, 20613924.
60. Katsnelson A, Tartakovsky JV, Miloro M. Review of the literature for mandibular metastasis illustrated by a case of lung metastasis to the temporomandibular joint in an HIV-positive patient. J Oral Maxillofac Surg 2010, 68:1960-1964. 10.1016/j.joms.2009.07.075, 20381938.